Schrodinger, Inc. income statement
In fiscal 2025, Schrodinger, Inc. reported revenue of $256m, up 23.3% on the year before, operating income of −$167m (a -65.2% margin) and net income of −$103m, or −$1.41 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.
Income statement
| Fiscal year | 2019Dec 2019 | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMJun 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 86 | 108 | 138 | 181 | 217 | 208 | 256 | 259 |
| Cost of revenue | 36 | 45 | 72 | 80 | 76 | 75 | 113 | 112 |
| Gross profit | 49 | 63 | 66 | 101 | 141 | 132 | 143 | 147 |
| Research and development | 39 | 65 | 91 | 126 | 182 | 202 | 173 | 169 |
| Selling and marketing | 21 | 18 | 22 | 31 | 37 | 40 | 41 | 42 |
| General and administrative | 27 | 42 | 64 | 91 | 99 | 100 | 95 | 90 |
| Operating income | −39 | −61 | −111 | −147 | −177 | −209 | −167 | −153 |
| Income before tax | −26 | −26 | −101 | −149 | 43 | −186 | −102 | −52 |
| Income tax | −0 | 0 | 0 | 0 | 2 | 1 | 1 | 2 |
| Net income | −25 | −24 | −100 | −149 | 41 | −187 | −103 | −54 |
| Diluted EPS | −$0.41 | −$0.41 | −$1.42 | −$2.10 | $0.54 | −$2.57 | −$1.41 | −$0.73 |
| Diluted shares (average) | 60m | 60m | 71m | 71m | 75m | 73m | 73m | 74m |
| EBITDA | −35 | −57 | −109 | −142 | −172 | −203 | −161 | −148 |
| Quarter | 2024 Q3Sept 2024 | 2024 Q4Dec 2024 | 2025 Q1Mar 2025 | 2025 Q2Jun 2025 | 2025 Q3Sept 2025 | 2025 Q4Dec 2025 | 2026 Q1Mar 2026 | 2026 Q2Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 35 | 88 | 60 | 55 | 54 | 87 | 59 | 59 |
| Cost of revenue | 18 | 24 | 28 | 29 | 26 | 30 | 29 | 26 |
| Gross profit | 18 | 64 | 31 | 26 | 28 | 57 | 30 | 32 |
| Research and development | 51 | 49 | 46 | 43 | 43 | 41 | 44 | 41 |
| Selling and marketing | 10 | 10 | 10 | 11 | 10 | 10 | 12 | 10 |
| General and administrative | 25 | 26 | 26 | 25 | 22 | 23 | 23 | 23 |
| Operating income | −68 | −21 | −51 | −53 | −46 | −17 | −49 | −42 |
| Income before tax | −38 | −39 | −60 | −43 | −33 | 33 | −60 | 7 |
| Income tax | −0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 |
| Net income | −38 | −40 | −60 | −43 | −33 | 33 | −60 | 6 |
| Diluted EPS | −$0.52 | −$0.55 | −$0.82 | −$0.59 | −$0.45 | $0.44 | −$0.81 | $0.08 |
| EBITDA | −67 | −19 | −49 | −51 | −44 | −16 | −47 | −40 |
Compare with peers
- Mesa Laboratories Inc income statement
- Maravai Lifesciences Holdings, Inc. income statement
- Fulgent Genetics, Inc. income statement
- Cytek Biosciences, Inc. income statement
- Castle Biosciences Inc income statement
Head to head: MLAB vs SDGRMRVI vs SDGRFLGT vs SDGRCSTL vs SDGR
More: Life Sciences Tools & Services stocks compared, Health Care sector, rankings of US companies